Adaptin Bio, Inc. Files Form 10-K/A Amendment: What Investors Need to Know
Key Highlights of the Filing
- Amendment Filed: Adaptin Bio, Inc. (the “Company”) has filed an Amendment No. 1 to its Annual Report on Form 10-K for the fiscal year ended December 31, 2025 (“Form 10-K/A”).
- Purpose of the Amendment: The amendment is being filed solely to update Item 15(b) and Exhibit 23.1 to include an amended consent from its independent registered public accounting firm, WithumSmith+Brown, PC. This update ensures the consent now references a registration statement that was inadvertently omitted in the original filing.
- No Changes to Financials: The amendment does not modify any financial or other information previously reported in the Original Form 10-K. There are no restatements or corrections to previously issued financial statements.
- Auditor’s Going Concern Warning: The auditor’s consent explicitly includes an explanatory paragraph regarding “substantial doubt over the Company’s ability to continue as a going concern.” This is a significant risk factor for investors and may be price sensitive.
- Company Status: As of June 11, 2026, there were 8,903,229 shares of common stock outstanding. The public float as of June 30, 2025, was approximately \$9.3 million.
-
Filer Status & Compliance:
- Non-accelerated filer
- Smaller reporting company
- Emerging growth company
- Not a well-known seasoned issuer; not a shell company
- In compliance with all reporting requirements and interactive data submissions
- No Trading Symbol: The company has no securities registered under Section 12(b) of the Exchange Act, and there is no trading symbol listed.
Details and Potential Price-Sensitive Information
- Going Concern Uncertainty: The most important and potentially price-moving disclosure is the auditor’s warning of “substantial doubt” about the company’s ability to continue as a going concern. This means the auditor believes there is significant risk that the company may not have sufficient resources to operate for the foreseeable future (typically one year from the date of the report), unless it can secure additional funding or improve its financial performance. Such a disclosure is likely to impact investor sentiment and could adversely affect the share price.
- Purpose of the Amendment: The amendment itself is mainly administrative, updating the auditor’s consent to include reference to a registration statement related to the company. There are no new financials, no restatements, and no changes to previously reported financial results or disclosures, which means the operational and financial snapshot of the company remains unchanged.
-
Exhibits Filed: The Form 10-K/A includes a comprehensive list of exhibits, such as:
- Amended and Restated Certificate of Incorporation and Bylaws
- Descriptions and forms of securities and warrants
- Key agreements, including research and lock-up agreements
- Certification of CEO and CFO under Sarbanes-Oxley Act
- Updated auditor consent (Exhibit 23.1)
However, no new material contracts or significant events are disclosed in this amendment.
What Should Shareholders and Potential Investors Watch?
- Liquidity and Going Concern: The company’s ability to continue as a going concern is the most critical issue. Investors should closely monitor future filings for updates on liquidity, cash flow, capital raising activities, or other actions to address this risk.
- Regulatory and Filing Compliance: There are no indications of late filings or non-compliance. The company is up to date with its SEC reporting obligations.
- Share Structure: With a relatively small public float (\$9.3 million) and 8.9 million shares outstanding, the stock may be subject to volatility if news or events impact market sentiment.
Conclusion
While the filing of this Form 10-K/A is primarily administrative and does not introduce new financial information or corrections, the reiteration of the “going concern” risk by the auditor remains a central issue for current and prospective shareholders. Investors should consider this risk when evaluating the company and monitor future filings and press releases for any developments regarding the company’s financial position and ability to continue operations.
Disclaimer: This article is for informational purposes only and does not constitute investment advice or an offer to buy or sell securities. Investors should review the full filing on the SEC’s website and consult with their financial adviser before making any investment decisions. The author assumes no responsibility for investment actions taken based on this article.
